  |
Investment Highlights
Strong revenue growth
• 5 year Compounded Annual Growth Rate of 32%
Healthy, robust business
• Generated 39.2 million of EBITDA in 2009 or $2.25 per share
Rich, near-term pipeline for growth
• 3 products awaiting regulatory approval
• 13 products in phase I, II and III
Financial data for ten years
|
(In thousands of Canadian dollars except for share and per share amounts) |
2009 |
2008 |
2007 |
2006 |
2005 |
2004 |
2003 |
2002 |
2001 |
2000 |
| Revenues |
109,693 |
82,744 |
62,941 |
48,357 |
33,689 |
27,871 |
23,788 |
23,277 |
17,497 |
12,381 |
|
Net Income (Loss) |
37,738 |
13,798 |
9,033 |
5,806 |
3,254 |
3,239 |
(4,172) |
5,162 |
1,485 |
2,797 |
|
Earnings (Loss) Per Share (Basic) |
2.23 |
0.93 |
0.60 |
0.39 |
0.22 |
0.22 |
(0.28) |
0.37 |
0.12 |
0.24 |
|
EBITDA |
39,183 |
29,021 |
19,913 |
15,420 |
9,230 |
7,571 |
4,457 |
8,301 |
4,982 |
2,860 |
|
Cash & marketable securities |
105,369 |
21,342 |
36,216 |
36,074 |
42,085 |
42,124 |
42,319 |
45,612 |
22,448 |
24,339 |
| Shareholders' Equity |
194,802 |
95,348 |
82,000 |
73,741 |
66,250 |
63,192 |
59,332 |
63,178 |
37,836 |
35,769 |
|
Shares issued and outstanding
|
18,563,250 |
14,921,446 |
14,902,784 |
14,980,131 |
14,732,368 |
14,858,469 |
14,799,588 |
14,780,205 |
12,539,247 |
12,394,038 |
|
|
